Tingting B. Zhang

Taiyuan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Risk and Survival Outcomes of Secondary Primary Malignancies in Chinese Lymphoma Patients in the Era of Modern Targeted Therapies: A Single-Center Retrospective Cohort Study.

Risk and Survival Outcomes of Secondary Primary Malignancies in Chinese Lymphoma Patients in the Era of Modern Targeted Therapies: A Single-Center Retrospective Cohort Study.

Journal: Blood and lymphatic cancer : targets and therapy

Published: April 20, 2026

Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance.

Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance.

Journal: Frontiers in immunology

Published: January 26, 2026

Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.

Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.

Journal: Leukemia

Published: December 03, 2024

Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.

Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.

Journal: British journal of haematology

Published: May 10, 2024

Genetic characteristics and clinical analysis of 20 patients with Gaucher's disease

Genetic characteristics and clinical analysis of 20 patients with Gaucher's disease

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: March 25, 2024

Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference.

Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference.

Journal: Frontiers in immunology

Published: February 21, 2024

Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.

Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.

Journal: American journal of hematology

Published: September 14, 2023

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.

Journal: Journal of hematology & oncology

Published: April 14, 2023

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.

Journal: Experimental hematology & oncology

Published: March 14, 2023

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing.

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing.

Journal: Frontiers in immunology

Published: November 08, 2022

Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome.

Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome.

Journal: International journal of cancer

Published: June 21, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026